• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.

    4/4/25 3:49:25 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care
    Get the next $NVRO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)


    NEVRO CORP

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    64157F103

    (CUSIP Number)


    DAVID GOLDMAN
    GAMCO INVESTORS, INC., ONE CORPORATE CENTER
    RYE, NY, 10580
    9149215000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/03/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GAMCO INVESTORS, INC. ET AL
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GABELLI FUNDS LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, IA



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GAMCO Asset Management Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, IA



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GABELLI & Co INVESTMENT ADVISERS, INC.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, IA



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GGCP, INC.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    WYOMING
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    Associated Capital Group, Inc.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    CO, HC



    SCHEDULE 13D

    CUSIP No.
    64157F103


    1 Name of reporting person

    GABELLI MARIO J
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.001 per share
    (b)Name of Issuer:

    NEVRO CORP
    (c)Address of Issuer's Principal Executive Offices:

    1800 BRIDGE PARKWAY, 1800 BRIDGE PARKWAY, REDWOOD CITY, CALIFORNIA , 94065.
    Item 2.Identity and Background
    (a)
    This statement is being filed by one or more of the following persons: GGCP, Inc. (GGCP), GGCP Holdings LLC (GGCP Holdings), GAMCO Investors, Inc. (GBL), Associated Capital Group, Inc. (AC), Gabelli Funds, LLC (Gabelli Funds), GAMCO Asset Management Inc. (GAMCO), Teton Advisors, LLC (Teton Advisors), Keeley-Teton Advisors, LLC (Keeley-Teton), Gabelli & Company Investment Advisers, Inc. (GCIA), Morgan Group Holding Co., (MGH), G.research, LLC (G.research), MJG Associates, Inc. (MJG Associates), Gabelli Securities International (Bermuda) Limited (GSIL), Gabelli Foundation, Inc. (Foundation), Mario Gabelli, LICT and CIBL. Those of the foregoing persons signing this Schedule 13D are hereinafter referred to as the Reporting Persons.
    (b)
    GAMCO is a New York corporation and GBL and MGH are Delaware corporations, each having its principal business office at One Corporate Center, Rye, New York 10580. GGCP is a Wyoming corporation and AC and GCIA are Delaware corporations each having its principal business office 191 Mason Street, Greenwich, CT 06830. GGCP Holdings is a Delaware limited liability corporation having its principal business office at 191 Mason Street, Greenwich, CT 06830. G.research is a Delaware limited liability company having its principal officers at One Corporate Center, Rye, New York 10580. Gabelli Funds is a New York limited liability company having its principal business office at One Corporate Center, Rye, New York 10580. Teton Advisors is a Delaware limited liability company having its principal place of business at 189 Mason Street, Greenwich, CT 06830. Keeley-Teton Advisors is a Delaware limited liability company having its principal place of business at 141 W. Jackson Blvd., Chicago, IL 60604. MJG Associates is a Connecticut corporation having its principal business office at 191 Mason Street, Greenwich, CT 06830. The Foundation is a Nevada corporation having its principal offices at 165 West Liberty Street, Reno, Nevada 89501. LICT is a Delaware corporation having its principal place of business as 401 Theodore Fremd Avenue, Rye, New York 10580. CIBL, Inc. is a Delaware corporation having its principal place of business as 165 West Liberty Street, Suite 220, Reno, NV 89501.
    (c)
    GGCP makes investments for its own account and is the manager and a member of GGCP Holdings which is the controlling shareholder of GBL and AC. GBL, a public company whose stock is quoted on the OTCQX platform, is the parent company for a variety of companies engaged in the securities business, including certain of those named below. AC, a public company listed on the New York Stock Exchange, is the parent company for a variety of companies engaged in the securities business, including certain of those listed below. GAMCO, a wholly-owned subsidiary of GBL, is an investment adviser registered under the Investment Advisers Act of 1940, as amended (Advisers Act). GAMCO is an investment manager providing discretionary managed account services for employee benefit plans, private investors, endowments, foundations and others. GCIA, a wholly owned subsidiary of AC, is an investment adviser registered under the Advisers Act and serves as a general partner or investment manager to limited partnerships and offshore investment companies and other accounts. As a part of its business, GCIA may purchase or sell securities for its own account. GCIA or its relying advisers, act as a general partner or investment manager of a number of funds or partnerships, including Gabelli Associates Fund, L.P., Gabelli Associates Fund II, L.P., Gabelli Associates Limited, Gabelli Associates Limited II E, Gabelli Intermediate Credit Fund L.P., GAMA Select Plus Master Fund, Ltd., GAMCO Medical Opportunities L.P., and Gabelli Multimedia Partners, L.P. G.research is a wholly owned subsidiary of MGH. G.research, is a broker-dealer registered under the Securities Exchange Act of 1934, as amended (1934 Act), which may as a part of its business purchase and sell securities for its own account. Gabelli Funds, a wholly owned subsidiary of GBL, is a limited liability company. Gabelli Funds is an investment adviser registered under the Advisers Act which provides advisory services for The Gabelli Equity Trust Inc., The Gabelli Asset Fund, The Gabelli Growth Fund, The Gabelli Convertible and Income Securities Fund Inc., The Gabelli Value 25 Fund Inc., The Gabelli Small Cap Growth Fund, The Gabelli Equity Income Fund, The Gabelli ABC Fund, The Gabelli Global Content & Connectivity Fund, The Gabelli Gold Fund, Inc., The Gabelli Multimedia Trust Inc., The Gabelli Global Rising Income & Dividend Fund, The Gabelli Capital Asset Fund, The Gabelli International Growth Fund, Inc., The Gabelli Global Growth Fund, The Gabelli Utility Trust, The Gabelli Utilities Fund, The Gabelli Dividend Growth Fund, The Gabelli Focused Growth and Income Fund, The Comstock Capital Value Fund, The Gabelli Dividend and Income Trust, The Gabelli Global Utility & Income Trust, The GAMCO Global Gold, Natural Resources, & Income Trust, The GAMCO Natural Resources, Gold & Income Trust, The GDL Fund, Gabelli Enterprise Mergers & Acquisitions Fund, The Gabelli ESG Fund, Inc., The Gabelli International Small Cap Fund, The Gabelli Healthcare & Wellness Rx Trust, The Gabelli Global Small and Mid Cap Value Trust, Gabelli Merger Plus+ Trust Plc, The Gabelli Global Financial Services Fund, The Gabelli Global Mini Mites Fund, The Gabelli Media Mogul Fund, The Gabelli Pet Parents Fund, The Gabelli U.S. Treasury Money Market Fund, Bancroft Fund Ltd. and Ellsworth Growth & Income Fund Ltd., Gabelli Growth Innovators ETF, Gabelli Love Our Planet & People ETF, Gabelli Automation ETF, Gabelli Commercial Aerospace & Defense ETF, Gabelli Financial Services Opportunities ETF (collectively, the Funds), which are registered investment companies. Gabelli Funds is also the investment adviser to The GAMCO International SICAV (sub-funds GAMCO Merger Arbitrage and GAMCO All Cap Value), a UCITS III vehicle. Teton Advisors, an investment adviser registered under the Advisers Act, provides discretionary advisory services to The TETON Westwood Mighty Mitessm Fund, The TETON Convertible Securities Fund, The Teton Westwood Balanced Fund, and The TETON Westwood Equity Fund. The TETON Westwood Mighty Mites Fund and the Teton Convertible Securities Fund are subadvised by Gabelli Funds, and their holdings are included in this filing. Keeley-Teton, an investment adviser registered under the Advisers Act, provides discretionary advisory services to The Teton Westwood Smallcap Equity Fund, The Keeley Small Cap Dividend Value Fund, The Keeley Small-Mid Cap Value Fund, and The Keeley Mid Cap Dividend Value Fund, as well as to institutional and individual clients. MJG Associates provides advisory services to private investment partnerships and offshore funds. Mario Gabelli is the sole shareholder, director and employee of MJG Associates. MJG Associates is the Investment Manager of Gabelli International Limited and Gabelli Fund, LDC. Mario J. Gabelli is the general partner of Gabelli Performance Partnership, LP. The Foundation is a private foundation. Mario Gabelli is the Chairman, a Trustee and the Investment Manager of the Foundation. Elisa M. Wilson is the President of the Foundation. LICT is a holding company with operating subsidiaries engaged primarily in the rural telephone industry. LICT actively pursues new business ventures and acquisitions. LICT makes investments in marketable securities to preserve capital and maintain liquidity for financing their business activities and acquisitions and are not engaged in the business of investing, or trading in securities. Mario J. Gabelli is the Chief Executive Officer, a director, and substantial shareholder of LICT. CIBL is a holding company with interest in telecommunications operations, primarily in the rural telephone industry. CIBL actively pursues new business ventures and acquisitions. CIBL makes investments in marketable securities to preserve capital and maintain liquidity for financing their business activities and acquisitions and are not engaged in the business of investing, or trading in securities. Mario J. Gabelli is a director, and substantial shareholder of CIBL. Mario Gabelli is the controlling stockholder, co-Chief Executive Officer and a director of GGCP and Chairman and Chief Executive Officer of GBL. He is the Executive Chairman of AC. Mario Gabelli is also a member of GGCP Holdings. Mario Gabelli is the controlling shareholder of MGH and indirectly of Teton Advisors and Keeley-Teton Advisors.
    (d)
    Not applicable.
    (e)
    Not applicable.
    (f)
    United States
    Item 5.Interest in Securities of the Issuer
    (a)
    As a result of the completion of the acquisition of the Issuer by Globus Medical, Inc., the Reporting Persons no longer have beneficial ownership of any of the Issuer's shares.
    (c)
    Information with respect to all transactions in the Securities which were effected during the past sixty days or since the most recent filing on Schedule 13D, whichever is less, by each of the Reporting Persons and Covered Persons is set forth below: DATE SHARES PURCHASED PRICE /SOLD GABELLI & COMPANY INVESTMENT ADVISERS, INC. GABELLI ASSOCIATES FUND II 4/3/2025 -62,700 5.8500 GABELLI ASSOCIATES FUND 4/3/2025 -183,650 5.8500 GABELLI ASSOCIATES LIMITED II E 4/3/2025 -116,350 5.8500 GABELLI ASSOCIATES LIMITED 4/3/2025 -349,750 5.8500 GABELLI FUNDS, LLC GABELLI ABC FUND 4/3/2025 -101,500 5.8500 COMSTOCK CAPITAL VALUE FUND 4/3/2025 -10,000 5.8500 GABELLI ENTERPRISE M&A FUND 4/3/2025 -40,000 5.8500 GAMCO MERGER ARBITRAGE UCITS 4/3/2025 -515,950 5.8500 GDL FUND 4/3/2025 -565,000 5.8500 MERGER PLUS+ TRUST 4/3/2025 -90,500 5.8500 GAMCO ASSET MANAGEMENT INC. 4/3/2025 -88,500 5.8500 THE TRANSACTIONS ON 4/3/2025 ARE A RESULT OF THE COMPLETION OF THE ACQUISITION OF THE ISSUER BY GLOBUS MEDICAL, INC.
    (e)
    The Reporting Persons ceased to be beneficial owners of 5% or more of the Issuer's common stock on April 3, 2025.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    GAMCO INVESTORS, INC. ET AL
     
    Signature:PETER D. GOLDSTEIN
    Name/Title:GENERAL COUNSEL
    Date:04/04/2025
     
    GABELLI FUNDS LLC
     
    Signature:DAVID GOLDMAN
    Name/Title:GENERAL COUNSEL
    Date:04/04/2025
     
    GAMCO Asset Management Inc.
     
    Signature:DOUGLAS R. JAMIESON
    Name/Title:PRESIDENT
    Date:04/04/2025
     
    GABELLI & Co INVESTMENT ADVISERS, INC.
     
    Signature:DOUGLAS R. JAMIESON
    Name/Title:PRESIDENT
    Date:04/04/2025
     
    GGCP, INC.
     
    Signature:DAVID GOLDMAN
    Name/Title:ATTORNEY-IN-FACT
    Date:04/04/2025
     
    Associated Capital Group, Inc.
     
    Signature:PETER D. GOLDSTEIN
    Name/Title:CHIEF LEGAL OFFICER
    Date:04/04/2025
     
    GABELLI MARIO J
     
    Signature:DAVID GOLDMAN
    Name/Title:ATTORNEY-IN-FACT
    Date:04/04/2025
    Get the next $NVRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVRO

    DatePrice TargetRatingAnalyst
    2/10/2025$4.50 → $5.85Underperform → Hold
    Jefferies
    2/7/2025$6.00 → $5.85Neutral → Overweight
    Piper Sandler
    12/3/2024$5.00Equal Weight
    Wells Fargo
    12/2/2024$9.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    8/9/2024Sell → Neutral
    Citigroup
    8/8/2024Underperform → Peer Perform
    Wolfe Research
    8/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024Neutral → Underweight
    JP Morgan
    More analyst ratings

    $NVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nevro upgraded by Jefferies with a new price target

      Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously

      2/10/25 7:02:54 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Nevro from Neutral to Overweight and set a new price target of $5.85 from $6.00 previously

      2/7/25 8:27:53 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Nevro with a new price target

      Wells Fargo initiated coverage of Nevro with a rating of Equal Weight and set a new price target of $5.00

      12/3/24 7:38:11 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Nevro Enters Into Cooperation Agreement With Engaged Capital

      Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi

      2/21/24 4:06:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Appoints Jon R. Shear as Vice President, Corporate Development

      REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately.   "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and

      4/19/21 7:00:00 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

      REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately.   "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a

      11/30/20 7:00:00 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

      AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

      2/6/25 9:30:21 AM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

      REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induceme

      1/21/25 4:30:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nevro Corp.

      SC 13G - NEVRO CORP (0001444380) (Subject)

      12/4/24 4:27:18 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Nevro Corp.

      SC 13D/A - NEVRO CORP (0001444380) (Subject)

      11/14/24 5:31:36 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nevro Corp.

      SC 13G/A - NEVRO CORP (0001444380) (Subject)

      11/14/24 5:18:25 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:33 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:35 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:38 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Nevro Corp.

      15-12G - NEVRO CORP (0001444380) (Filer)

      4/14/25 8:30:09 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Nevro Corp.

      EFFECT - NEVRO CORP (0001444380) (Filer)

      4/8/25 12:15:06 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.

      SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)

      4/4/25 3:49:25 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Financials

    Live finance-specific insights

    See more
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

      AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

      2/6/25 9:30:21 AM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Reports Third-Quarter 2024 Financial Results

      Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma

      11/11/24 4:05:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care